944 Stock Overview
Manufactures and distributes microbiological media, reagents, and equipment for in vitro diagnostics in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
BioMaxima S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł3.19 |
| 52 Week High | zł4.94 |
| 52 Week Low | zł2.56 |
| Beta | -2.4 |
| 11 Month Change | 4.59% |
| 3 Month Change | 9.62% |
| 1 Year Change | -33.19% |
| 33 Year Change | -47.36% |
| 5 Year Change | n/a |
| Change since IPO | -49.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| 944 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -4.2% | -3.5% | 0.8% |
| 1Y | -33.2% | 2.2% | 6.1% |
Return vs Industry: 944 underperformed the German Medical Equipment industry which returned 2.2% over the past year.
Return vs Market: 944 underperformed the German Market which returned 6.1% over the past year.
Price Volatility
| 944 volatility | |
|---|---|
| 944 Average Weekly Movement | 6.6% |
| Medical Equipment Industry Average Movement | 4.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 944 has not had significant price volatility in the past 3 months.
Volatility Over Time: 944's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 115 | Lukasz Urban | www.biomaxima.com |
BioMaxima S.A. manufactures and distributes microbiological media, reagents, and equipment for in vitro diagnostics in Poland. Its primary products include analyzers and diagnostic reagents for testing the biochemical parameters of blood and other body fluids; systems for the determination of drug resistance of microorganisms; quick diagnostic tests for detecting infectious diseases, cancer markers, heart attack markers, and addictive substances and readers; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers for professional use; and analyzers for gasometric tests and critical blood parameters tests. The company also provides surfaces and air controls; antibiotics discs and MIC strips; and chromogenic, dehydrated, and prepared culture media; additives and supplements for media; microbank microorganism storage systems; and veterinary products.
BioMaxima S.A. Fundamentals Summary
| 944 fundamental statistics | |
|---|---|
| Market cap | €15.28m |
| Earnings (TTM) | €84.30k |
| Revenue (TTM) | €11.03m |
181.2x
P/E Ratio1.4x
P/S RatioIs 944 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 944 income statement (TTM) | |
|---|---|
| Revenue | zł47.24m |
| Cost of Revenue | zł24.93m |
| Gross Profit | zł22.31m |
| Other Expenses | zł21.95m |
| Earnings | zł361.00k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Sep 30, 2024
| Earnings per share (EPS) | 0.086 |
| Gross Margin | 47.23% |
| Net Profit Margin | 0.76% |
| Debt/Equity Ratio | 25.5% |
How did 944 perform over the long term?
See historical performance and comparison